1 unchanged sentence
The following exhibits are filed as part of this report:
−Removed: Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Form 6-K filed on May 18, 2017).
−Removed: Omnibus Amendment to Equity Awards between the Company and Elizabeth Barrett, dated January 19, 2021
−Removed: Amendment 1 to Employment Agreement between the Company and Elizabeth Barrett, dated January 26, 2021
−Removed: Amendment 1 to Employment Agreement between the Company and Mark Schoenberg, dated January 26, 2021
−Removed: Amendment 1 to Employment Agreement between the Company and Jason Smith, dated January 26, 2021
−Removed: Amendment 2 to Employment Agreement between the Company and Mark Schoenberg, dated March 15, 2021
−Removed: Pre-Paid Forward Contract by and among the Registrant and RTW Investments ICAV for and on behalf of RTW Fund 2, dated as of March 18, 2021, as amended.
+Added: Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 6-K (File No.
+Added: 001-38079), filed with the SEC on May 18, 2017).
+Added: UroGen Pharma Ltd.
+Added: 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38079), filed with the SEC on June 8, 2021).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
UroGen Pharma Ltd.
+Added: August 4, 2021
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
+Added: August 4, 2021
/s/ Molly Henderson
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.